Filing Details
- Accession Number:
- 0001209191-20-054650
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-13 16:44:23
- Reporting Period:
- 2020-10-08
- Accepted Time:
- 2020-10-13 16:44:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682017 | Rodger Novak | C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139 | President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2020-10-08 | 22,238 | $14.43 | 670,245 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-10-08 | 22,238 | $100.00 | 648,007 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2020-10-09 | 2,762 | $14.43 | 650,769 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-10-09 | 2,762 | $100.00 | 648,007 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2020-10-08 | 22,238 | $0.00 | 22,238 | $14.43 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2020-10-09 | 2,762 | $0.00 | 2,762 | $14.43 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 193,077 | 2027-06-15 | No | 4 | M | Direct | |
| 190,315 | 2027-06-15 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.
Billionaire Hedge Funds
